Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Meningioma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 20Carboplatin 18Cisplatin 12Topotecan 6Docetaxel 5Gemcitabine 4Etoposide 3rubitecan 2Taxes 2Surgical Procedures, Operative 2Filgrastim 2Erlotinib Hydrochloride 2Cyclophosphamide 2vandetanib 1sargramostim 1pegfilgrastim 1motesanib diphosphate 1liposomal doxorubicin 1liposomal amphotericin B 1Watchful Waiting 1Vorinostat 1Trabectedin 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Pemetrexed 1Ondansetron 1Neoadjuvant Therapy 1Mitoxantrone 1Mifepristone 1Mass Spectrometry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Carcinoma, Ovarian Epithelial × Mifepristone × Clear all
NCT00459290 2018-07-18

Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

GOG Foundation

Phase 2 Completed
24 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡